Vertex Pharmaceuticals Inc

VRTX: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|N%LOCK|<F@#LOCK|!HXyrmK

Vertex Earnings: Diversification Beyond CF Strengthens Long-Term Growth Outlook

Vertex reported third-quarter revenue of $3.4 billion, up 12% year over year, driven by continued growth in its cystic fibrosis franchise, which accounted for 95% of total product revenue. Vertex raised its 2026 revenue growth outlook by 38 basis points at the midpoint.

Sponsor Center